ArticleInternational journal of molecular sciences2026
The hsa_circ_0084050/miR-373-3p Axis Controls Bone Sialoprotein-Induced ADAM9 Upregulation to Drive Lung Cancer Progression and Metastasis.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer carries a high mortality burden, with metastatic dissemination accounting for much of its poor prognosis. Bone sialoprotein (BSP), a matricellular protein belonging to the SIBLING family, has been associated with tumor invasion; nonetheless, its role in lung cancer remains inadequately characterized. Clinical database analysis indicates that BSP is the most critical SIBLING protein associated with lung cancer proliferation and metastasis. Our clinical data also confirmed that BSP levels are higher in metastatic lung cancer compared to non-metastatic cases. We further demonstrate that BSP promotes lung cancer progression and motility through upregulated ADAM9 expression. Mechanistically, we revealed that BSP enhances ADAM9-dependent proliferation and motility via the FAK pathway. In addition, the hsa_circ_0084050/miR-373-3p regulatory axis contributes to BSP-mediated ADAM9 regulation. In an exploratory mouse metastasis model established by caudal artery injection of A549 control or stable BSP-shRNA cells into male BALB/c nude mice, BSP knockdown was associated with a lower metastatic tumor burden. Therefore, BSP may serve as a therapeutic target for limiting lung cancer progression and metastatic dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.